Liver-Kidney-Metabolic Health, Sex, and Menopause Impact Total Scores and Monovessel vs. Multivessel Coronary Artery Calcification

IF 3.4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Kamran Bagheri Lankarani, Mohamad Jamalinia, Fatemeh Zare, Seyed Taghi Heydari, Ali Ardekani, Amedeo Lonardo
{"title":"Liver-Kidney-Metabolic Health, Sex, and Menopause Impact Total Scores and Monovessel vs. Multivessel Coronary Artery Calcification","authors":"Kamran Bagheri Lankarani,&nbsp;Mohamad Jamalinia,&nbsp;Fatemeh Zare,&nbsp;Seyed Taghi Heydari,&nbsp;Ali Ardekani,&nbsp;Amedeo Lonardo","doi":"10.1007/s12325-025-03121-x","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Liver-kidney-metabolic health (LKMH) depends on complex interactions between metabolic dysfunction-associated steatotic liver disease (MASLD), chronic kidney disease (CKD), sex, and reproductive status. This study evaluates in a holistic manner how LKMH, sex, and menopause influence coronary artery calcification (CAC) burden.</p><h3>Methods</h3><p>Patients without previous cardiovascular disease were prospectively recruited. Liver fat was assessed via ultrasonography and categorized as mild or moderate-to-severe. CKD was classified using estimated glomerular filtration rate (eGFR). CAC burden was quantified as 0, 1–299, ≥ 300, single-vessel, or multivessel with coronary computed tomography. Stepwise backward multinomial logistic regression was applied for analysis.</p><h3>Results</h3><p>A total of 446 patients (59.2% female, average age 52.9 years) were included. Moderate-to-severe MASLD was independently associated with an increased risk of CAC 1–299 [OR 2.30 (1.21–4.36)], CAC ≥ 300 [OR 4.93 (1.46–16.59)], and single-vessel CAC [OR 2.03 (1.03–4.00)]. Mild MASLD [OR 2.47 (1.20–4.21)], moderate-to-severe MASLD [OR 3.74 (1.76–7.93)], and CKD stage 2 [OR 2.27 (1.26–4.08)] were independently associated with increased multivessel CAC risk. Liver fat content showed a dose–response association with CAC burden. Subgroup analysis revealed that MASLD and CKD increased CAC risk in male but not female patients, with menopause significantly modifying LKMH’s effect.</p><h3>Conclusion</h3><p>LKMH’s impact on CAC burden is significantly influenced by liver fat content, eGFR, sex, and menopause, suggesting that MASLD, CKD, sex, and reproductive status should be integrated into CAC risk prediction models.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 4","pages":"1729 - 1744"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03121-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Liver-kidney-metabolic health (LKMH) depends on complex interactions between metabolic dysfunction-associated steatotic liver disease (MASLD), chronic kidney disease (CKD), sex, and reproductive status. This study evaluates in a holistic manner how LKMH, sex, and menopause influence coronary artery calcification (CAC) burden.

Methods

Patients without previous cardiovascular disease were prospectively recruited. Liver fat was assessed via ultrasonography and categorized as mild or moderate-to-severe. CKD was classified using estimated glomerular filtration rate (eGFR). CAC burden was quantified as 0, 1–299, ≥ 300, single-vessel, or multivessel with coronary computed tomography. Stepwise backward multinomial logistic regression was applied for analysis.

Results

A total of 446 patients (59.2% female, average age 52.9 years) were included. Moderate-to-severe MASLD was independently associated with an increased risk of CAC 1–299 [OR 2.30 (1.21–4.36)], CAC ≥ 300 [OR 4.93 (1.46–16.59)], and single-vessel CAC [OR 2.03 (1.03–4.00)]. Mild MASLD [OR 2.47 (1.20–4.21)], moderate-to-severe MASLD [OR 3.74 (1.76–7.93)], and CKD stage 2 [OR 2.27 (1.26–4.08)] were independently associated with increased multivessel CAC risk. Liver fat content showed a dose–response association with CAC burden. Subgroup analysis revealed that MASLD and CKD increased CAC risk in male but not female patients, with menopause significantly modifying LKMH’s effect.

Conclusion

LKMH’s impact on CAC burden is significantly influenced by liver fat content, eGFR, sex, and menopause, suggesting that MASLD, CKD, sex, and reproductive status should be integrated into CAC risk prediction models.

Abstract Image

肝肾代谢健康、性别和绝经影响总分和单支vs多支冠状动脉钙化。
肝-肾-代谢健康(LKMH)取决于代谢功能障碍相关的脂肪变性肝病(MASLD)、慢性肾脏疾病(CKD)、性别和生殖状况之间复杂的相互作用。本研究以整体方式评估LKMH、性别和更年期如何影响冠状动脉钙化(CAC)负荷。方法:前瞻性招募既往无心血管疾病的患者。通过超声检查评估肝脏脂肪,并将其分为轻度或中度至重度。根据估计的肾小球滤过率(eGFR)对CKD进行分类。冠状动脉计算机断层扫描将CAC负荷量化为0,1 -299,≥300,单血管或多血管。采用逐步回归多项式逻辑回归进行分析。结果:共纳入446例患者,其中女性59.2%,平均年龄52.9岁。中度至重度MASLD与CAC 1-299 [OR 2.30(1.21-4.36)]、CAC≥300 [OR 4.93(1.46-16.59)]和单血管CAC [OR 2.03(1.03-4.00)]的风险增加独立相关。轻度MASLD [OR 2.47(1.20-4.21)]、中度至重度MASLD [OR 3.74(1.76-7.93)]和CKD 2期[OR 2.27(1.26-4.08)]与多血管CAC风险增加独立相关。肝脂肪含量与CAC负荷呈剂量反应关系。亚组分析显示,MASLD和CKD增加了男性患者的CAC风险,但没有增加女性患者的CAC风险,更年期显著改变了LKMH的作用。结论:LKMH对CAC负担的影响受肝脏脂肪含量、eGFR、性别、绝经期等因素的显著影响,建议将MASLD、CKD、性别、生殖状况纳入CAC风险预测模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Therapy
Advances in Therapy 医学-药学
CiteScore
7.20
自引率
2.60%
发文量
353
审稿时长
6-12 weeks
期刊介绍: Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信